...
首页> 外文期刊>Journal of cardiovascular electrophysiology >Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation.
【24h】

Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrillation.

机译:在山羊心房颤动模型中,维拉帕米对地高辛的心脏起搏作用。

获取原文
获取原文并翻译 | 示例

摘要

INTRODUCTION: Verapamil and digoxin have been shown to modulate tachycardia-induced atrial electrical remodeling. The goal of the present study was to determine the direct effects of verapamil and digoxin on atrial fibrillation (AF), before and after electrical remodeling. METHODS AND RESULTS: In six goats we measured the AF cycle length (AFCL) and duration of AF (DurAF) of 50 consecutive induced paroxysms, before (t = 0) and after 24 hours (t = 24) of electrical remodeling. During AF, conduction velocity (CV(AF)), refractory period (RP(AF)), and type of AF (I, II, III) were determined. Verapamil was administered at a loading dose of 0.1 mg/kg, followed by a continuous (2-hour) infusion of 5 microg/kg/min. Digoxin was given intravenously as a single 0.02 mg/kg bolus. At t = 0 and t = 24, digoxin and verapamil caused a significant slowing of the ventricular rate of >40%. Digoxin had no effect on DurAF, AFCL, CV(AF), or RP(AF). Infusion of verapamil had a direct proarrhythmic effect. Both at t = 0 and t = 24, AFCL and RP(AF) were shortened by about 15%. During acute AF, verapamil prolonged the average duration of AF paroxysms from 7 to 16 seconds. After 24 hours of AF, the proarrhythmic effect was much stronger. Shortly after starting infusion (6 +/- 2 min), verapamil converted paroxysmal AF into sustained AF. As long as verapamil infusion was maintained, AF no longer terminated in any of the goats. This effect was associated with an increase in AF fragmentation from type I to type II-III. CONCLUSION: Verapamil shortens AFCL and RP(AF) in the presence and absence of electrical remodeling. After 24 hours, it exerted a marked proarrhythmic effect and converted paroxysmal (type I) into sustained (type III) AF. In contrast, digoxin had no effect on the rate or stability of AF.
机译:简介:维拉帕米和地高辛已被证明可调节心动过速引起的心房电重构。本研究的目的是确定电重构前后维拉帕米和地高辛对房颤的直接作用。方法和结果:在六只山羊中,我们在电重构之前(t = 0)和24小时(t = 24)后测量了50个连续诱发的阵发性发作的AF周期长度(AFCL)和AF持续时间(DurAF)。在AF期间,确定传导速度(CV(AF)),不应期(RP(AF))和AF类型(I,II,III)。维拉帕米的给药剂量为0.1 mg / kg,然后连续(2小时)输注5 microg / kg / min。地高辛以0.02 mg / kg的单次推注静脉内给药。在t = 0和t = 24时,地高辛和维拉帕米引起​​的心室率显着减慢,> 40%。地高辛对DurAF,AFCL,CV(AF)或RP(AF)没有影响。输注维拉帕米具有直接的心律失常作用。在t = 0和t = 24时,AFCL和RP(AF)均缩短了约15%。在急性房颤期间,维拉帕米将房颤发作的平均持续时间从7秒延长到16秒。 AF 24小时后,心律不齐的效果要强得多。开始输注后不久(6 +/- 2分钟),维拉帕米将阵发性房颤转变为持续性房颤。只要维持维拉帕米输注,任何一只山羊的AF都不会终止。这种作用与AF碎片从I型到II-III型的增加有关。结论:在存在和不存在电重构的情况下,维拉帕米可缩短AFCL和RP(AF)。 24小时后,它发挥了明显的心律失常作用,并将阵发性(I型)转变为持续性(III型)AF。相反,地高辛对房颤的发生率或稳定性没有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号